Lupus Foundation of America Greater Ohio Chapter Logo

Toll Free: 1 (888) NO-LUPUS
Phone: (440) 717-0183

Help Us Solve The Cruel MysteryTM

Donate To The Ohio Chapter

New Drug Application for LUPKYNIS® Filed in Japan for Lupus Nephritis Treatment

by | Dec 7, 2023

Inside Lupus Research (ILR): Treatment News

Two pharmaceutical companies have partnered and submitted a new drug application to the Japanese Ministry of Health, Labour, and Welfare to manufacture and market the drug therapy, LUPKYNIS® (voclosporin), for the treatment of lupus nephritis, (LN, lupus-related kidney disease). 

LUPKYNIS is a novel, structurally modified calcineurin inhibitor (CNI) that works in two ways – acting as an immunosuppressant through inhibition of T-cell activation and cytokine production, and by promoting podocyte stability in the kidney. 

Continue to follow the Lupus Foundation of America for updates on lupus drug developments and clinical trials. Learn more about LUPKYNIS.

Read the announcement 

This post was originally published on this site

Skip to content